Lifeward Launches Direct Sales of AlterG Product Line in Germany
Lifeward (Nasdaq: LFWD) has announced the launch of direct sales for its AlterG product line in Germany, effective immediately. This strategic move, announced at the REHACARE 2024 conference in Düsseldorf, adds AlterG products to the company's German sales portfolio alongside the ReWalk Personal Exoskeleton.
The company expects several financial benefits from this direct sales approach, including increased revenue due to a more focused sales effort and higher margins with minimal additional investment. Lifeward aims to leverage its existing sales and support infrastructure in Germany to expand market penetration and accelerate its path to profitability both in Germany and globally.
While Lifeward begins direct sales, PHYSIOMED GROUP will continue to provide service and support to its existing base of nearly 500 customers in Germany and distribute AlterG units in parallel with the Lifeward team.
Lifeward (Nasdaq: LFWD) ha annunciato il lancio delle vendite dirette per la sua linea di prodotti AlterG in Germania, con effetto immediato. Questa mossa strategica, annunciata durante la conferenza REHACARE 2024 a Düsseldorf, aggiunge i prodotti AlterG al portafoglio di vendite dell'azienda in Germania, insieme all'Esoscheletro Personale ReWalk.
L'azienda prevede diversi vantaggi finanziari da questo approccio di vendita diretta, tra cui un aumento dei ricavi grazie a uno sforzo di vendita più mirato e margini più elevati con un investimento aggiuntivo minimo. Lifeward punta a sfruttare la sua infrastruttura di vendita e supporto esistente in Germania per espandere la penetrazione del mercato e accelerare il suo percorso verso la redditività sia in Germania che a livello globale.
Mentre Lifeward inizia le vendite dirette, il PHYSIOMED GROUP continuerà a fornire servizi e supporto alla sua base esistente di quasi 500 clienti in Germania e distribuirà le unità AlterG parallelamente al team di Lifeward.
Lifeward (Nasdaq: LFWD) ha anunciado el lanzamiento de ventas directas para su línea de productos AlterG en Alemania, con efecto inmediato. Este movimiento estratégico, anunciado en la conferencia REHACARE 2024 en Düsseldorf, añade productos AlterG al portafolio de ventas de la empresa en Alemania junto con el Exoesqueleto Personal ReWalk.
La compañía espera varios beneficios financieros de este enfoque de ventas directas, incluyendo un aumento de ingresos debido a un esfuerzo de ventas más enfocado y márgenes más altos con una inversión adicional mínima. Lifeward busca aprovechar su infraestructura de ventas y soporte existente en Alemania para expandir la penetración en el mercado y acelerar su camino hacia la rentabilidad tanto en Alemania como a nivel global.
Mientras Lifeward inicia las ventas directas, PHYSIOMED GROUP continuará proporcionando servicio y soporte a su base existente de casi 500 clientes en Alemania y distribuirá unidades de AlterG en paralelo con el equipo de Lifeward.
라이프워드 (Nasdaq: LFWD)는 AlterG 제품 라인의 독일 직접 판매 시작을 즉시 시행한다고 발표했습니다. 이 전략적 결정은 뒤셀도르프에서 열린 REHACARE 2024 컨퍼런스에서 발표되었으며, AlterG 제품을 ReWalk 개인 외골격과 함께 회사의 독일 판매 포트폴리오에 추가합니다.
회사는 보다 집중적인 판매 노력으로 인한 수익 증가와 최소한의 추가 투자를 통한 더 높은 마진을 포함하여 이 직접 판매 접근 방식에서 몇 가지 재정적 혜택을 기대하고 있습니다. 라이프워드는 독일에서 기존 판매 및 지원 인프라를 활용하여 시장 침투를 확대하고 독일 및 글로벌 차원에서 수익성 향상 속도를 가속화할 계획입니다.
라이프워드가 직접 판매를 시작하는 동안, PHYSIOMED GROUP은 독일의 500명 가까운 기존 고객에게 서비스와 지원을 계속 제공하며 라이프워드 팀과 병행하여 AlterG 유닛을 배포합니다.
Lifeward (Nasdaq: LFWD) a annoncé le lancement des ventes directes pour sa gamme de produits AlterG en Allemagne, avec effet immédiat. Ce mouvement stratégique, annoncé lors de la conférence REHACARE 2024 à Düsseldorf, ajoute les produits AlterG au portefeuille de ventes de l'entreprise en Allemagne, en plus de l'Exosquelette Personnel ReWalk.
La société s'attend à plusieurs bénéfices financiers grâce à cette approche de vente directe, notamment une augmentation des revenus en raison d'un effort de vente plus ciblé et des marges plus élevées avec un investissement additionnel minimal. Lifeward vise à tirer parti de son infrastructure de vente et de support existante en Allemagne pour accroître sa pénétration du marché et accélérer son chemin vers la rentabilité, tant en Allemagne qu'à l'échelle mondiale.
Alors que Lifeward commence les ventes directes, le PHYSIOMED GROUP continuera à fournir services et support à sa base existante de près de 500 clients en Allemagne et à distribuer les unités AlterG parallèlement à l'équipe de Lifeward.
Lifeward (Nasdaq: LFWD) hat den Start des Direktvertriebs für seine AlterG-Produktlinie in Deutschland bekannt gegeben, der sofort wirksam ist. Dieser strategische Schritt, der auf der REHACARE 2024-Konferenz in Düsseldorf angekündigt wurde, fügt die AlterG-Produkte zum Verkaufsportfolio des Unternehmens in Deutschland hinzu, das bereits das persönliche Exoskelett ReWalk umfasst.
Das Unternehmen erwartet von diesem Direktvertriebsansatz mehrere finanzielle Vorteile, darunter höhere Einnahmen durch einen fokussierteren Verkaufsansatz und höhere Margen mit minimalen zusätzlichen Investitionen. Lifeward plant, seine bestehende Vertriebs- und Unterstützungsinfrastruktur in Deutschland zu nutzen, um die Marktpenetration zu erhöhen und den Weg zur Rentabilität sowohl in Deutschland als auch global zu beschleunigen.
Während Lifeward mit dem Direktvertrieb beginnt, wird die PHYSIOMED GROUP weiterhin Service und Unterstützung für ihre bestehenden fast 500 Kunden in Deutschland anbieten und AlterG-Geräte parallel zum Team von Lifeward vertreiben.
- Direct sales expected to improve margins and increase AlterG revenues in Germany
- Utilization of existing sales and support infrastructure for minimal additional investment
- Potential for expanded market penetration through more aggressive selling and marketing
- Accelerated path to profitability in Germany and globally
- None.
Insights
The transition to direct sales of AlterG products in Germany marks a significant strategic shift for Lifeward. This move is expected to yield several financial benefits:
- Improved profit margins by eliminating distributor costs
- Increased revenue through more focused sales efforts
- Minimal additional investment due to leveraging existing infrastructure
- Potential for accelerated path to profitability in Germany and globally
While specific financial projections aren't provided, the company's emphasis on margin improvement and revenue growth suggests a positive outlook. However, investors should monitor the execution of this strategy, particularly how quickly Lifeward can ramp up direct sales and whether it can effectively manage the transition from the previous distribution model. The retention of PHYSIOMED GROUP for existing customer support mitigates some transition risks.
Given Lifeward's current market cap of
Lifeward's decision to directly sell AlterG products in Germany is a strategic move in the competitive medical device market. Key points to consider:
- Germany is a important market for rehabilitation devices, with a well-developed healthcare system and aging population
- Direct sales allow for better control over marketing and customer relationships
- The addition of AlterG to ReWalk in Lifeward's German portfolio creates a more comprehensive rehabilitation offering
- The launch coincides with REHACARE 2024, a major industry event, potentially boosting initial visibility and sales
The introduction of the new AlterG NEO at REHACARE suggests product innovation is ongoing, which is vital in this sector. The existing base of 500 customers provides a strong foundation for upselling and referrals. However, success will depend on Lifeward's ability to effectively market and differentiate its products in a competitive landscape. Investors should watch for indicators of market reception, sales growth and any shifts in market share following this strategic change.
Direct sales of AlterG products through the Lifeward GmbH sales team expected to improve margins and increase AlterG revenues in Germany, accelerating Lifeward’s path to profitability
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced today that it will begin selling the AlterG family of products through its German sales organization, effective immediately. The announcement was made at today’s REHACARE 2024 conference in Düsseldorf, Germany, where the new AlterG NEO will be available for live demonstrations and purchase.
The move adds the AlterG product line to the ReWalk Personal Exoskeleton in Lifeward’s German sales portfolio. The Company expects several financial benefits from selling directly, including greater revenue due to a more focused sales effort and higher margins with little incremental investment by utilizing its existing sales and support infrastructure in Germany.
“We believe that there is significant potential to expand penetration of the German market through a more aggressive selling and marketing approach. By leveraging Lifeward’s direct sales organization and infrastructure, we believe we are better positioned to meet the needs of the market and do so more efficiently with higher margins,” said Larry Jasinski, Chief Executive Officer. “By realigning our focus on growing the AlterG revenues in Germany, we believe we can accelerate our path to profitability in Germany and globally.”
“Our team in Germany is poised capitalize on our existing relationships with customers to grow the German market for AlterG,” said Charles Remsberg, Chief Sales Officer. “With the experience we gained earlier this year in the US, we are confident that we have the team and plan in place to maximize our efficiencies and dedicate our attention to growing the ReWalk and AlterG markets in Germany.”
AlterG products have been available to customers in Germany since 2013 through a distribution arrangement with PHYSIOMED GROUP (formerly proxomed Medizintechnik GmbH). Under this existing contract, PHYSIOMED GROUP will continue to provide service and support to its existing base of nearly 500 customers in Germany and will continue to distribute AlterG units in parallel with the Lifeward team.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek," and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Lifeward’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in the Company’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in the Company’s annual report on Form 10-K and 10-K/A, as amended, for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Lifeward Media Relations:
Kathleen O’Donnell
VP Marketing & New Business Development
Lifeward
E: media@golifeward.com
Lifeward Investor Contact:
Michael Lawless
Chief Financial Officer
Lifeward
E: ir@golifeward.com
FAQ
What products will Lifeward (LFWD) start selling directly in Germany?
Where was Lifeward's (LFWD) direct sales announcement for AlterG products made?
What are the expected financial benefits for Lifeward (LFWD) from direct sales in Germany?
How long have AlterG products been available in Germany before Lifeward's (LFWD) direct sales initiative?
